What are your thoughts on the controversy of COVID-19 thrombotic microangiopathy and how to treat it?

COVID-19 hypercoagulability is a dynamic topic of research. There appears to be controversy on COVID-19 associated TMA and if TMA-directed therapies would be effective in that scenario. There is data to suggest the process may be complement-mediated. In a COVID-19 positive patient with normal ADAMTS13 but evidence of a MAHA. How would you approach the diagnosis/management of such a patient?